Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach

Clin Liver Dis. 2021 May;25(2):311-326. doi: 10.1016/j.cld.2021.01.004. Epub 2021 Mar 10.

Abstract

Nonselective beta-blockers represent the mainstay of medical therapy in the prophylaxis of variceal bleeding and rebleeding in patients with portal hypertension. Their efficacy has been demonstrated by numerous trials; however, there exist safety concerns in advanced disease, such as in patients with refractory ascites. Importantly, nonselective beta-blockers also exert nonhemodynamic beneficial effects that may contribute to a prolonged decompensation-free survival, as recently shown in the PREDESCI trial. This review summarizes the current evidence on nonselective beta-blocker therapy and proposes a tailored, patient-centered approach for the use of nonselective beta-blockers in patients with portal hypertension.

Keywords: Adrenergic beta blockers; Portal hypertension; Variceal bleeding.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Esophageal and Gastric Varices* / drug therapy
  • Gastrointestinal Hemorrhage / prevention & control
  • Humans
  • Hypertension, Portal* / complications
  • Hypertension, Portal* / drug therapy
  • Varicose Veins*

Substances

  • Adrenergic beta-Antagonists